BiondVax Pharmaceuticals Insiders
BVXVDelisted Stock | USD 1.35 0.03 2.17% |
BiondVax Pharmaceuticals employs about 33 people. The company is managed by 6 executives with a total tenure of roughly 20 years, averaging almost 3.0 years of service per executive, having 5.5 employees per reported executive. Recap of BiondVax Pharmaceuticals' management performance can provide insight into the venture performance.
Tamar BenYedidia Executive Chief Scientific Officer |
BiondVax |
BiondVax Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3089) % which means that it has lost $0.3089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (56.0153) %, meaning that it created substantial loss on money invested by shareholders. BiondVax Pharmaceuticals' management efficiency ratios could be used to measure how well BiondVax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.BiondVax Pharmaceuticals Workforce Comparison
BiondVax Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 959. BiondVax Pharmaceuticals holds roughly 33.0 in number of employees claiming about 3% of equities under Health Care industry.
BiondVax Pharmaceuticals Notable Stakeholders
A BiondVax Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BiondVax Pharmaceuticals often face trade-offs trying to please all of them. BiondVax Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BiondVax Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
CPA CPA | Chief Officer | Profile | |
BSc Eng | Chief Officer | Profile | |
Tamar BenYedidia | Chief Scientific Officer | Profile | |
Dalit Fischer | Head RD | Profile | |
MSc MBA | CEO Director | Profile | |
Moran LLB | Chief Staff | Profile |
About BiondVax Pharmaceuticals Management Performance
The success or failure of an entity such as BiondVax Pharmaceuticals often depends on how effective the management is. BiondVax Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BiondVax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BiondVax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel. Biondvax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Please note, the imprecision that can be found in BiondVax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BiondVax Pharmaceuticals. Check BiondVax Pharmaceuticals' Beneish M Score to see the likelihood of BiondVax Pharmaceuticals' management manipulating its earnings.
BiondVax Pharmaceuticals Workforce Analysis
Traditionally, organizations such as BiondVax Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BiondVax Pharmaceuticals within its industry.BiondVax Pharmaceuticals Manpower Efficiency
Return on BiondVax Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 175.6K | |
Net Loss Per Executive | 966K | |
Working Capital Per Employee | 364.6K | |
Working Capital Per Executive | 2M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |